Annexon, Inc. (ANNX)

In the past six months, Annexon's stock price has been influenced by the Q4/Full-Year 2025 earnings release, clinical trial updates, analyst attention, institutional interest, and a public offering with insider purchases. The company reported Q4 2025 EPS of -$0.28, beating estimates, and reaffirmed its cash runway into H2 2027. Positive updates on its pipeline and the European MAA filing for tanruprubart (ANX005) have positively impacted sentiment. Renewed analyst attention and increased institutional holdings have supported the stock. A public offering raised approximately $86.25 million, and a director's insider purchase signaled confidence. The stock price saw a significant increase of 237.42% between April 7, 2025, and April 2, 2026. The 52-week low was $1.28 and the 52-week high was $7.18.

The demand for Annexon's products and services is unlikely to exhibit significant seasonality, as the need for these treatments is driven by disease prevalence and progression rather than seasonal factors. As a pre-revenue company, its current "demand" is primarily in the form of investor interest and clinical trial enrollment, which are not typically seasonal.

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for classical complement-mediated disorders. The company's core business revolves around its proprietary platform technology, which targets C1q to block neuroinflammatory cascades. Its pipeline includes ANX005 for Guillain-Barré Syndrome, Huntington's disease, and amyotrophic lateral sclerosis; ANX007 (vonaprument) for geographic atrophy; ANX1502 for autoimmune indications; and ANX009 for lupus nephritis.

Annexon, Inc. is headquartered in Brisbane, California, United States. While its corporate office is in the U.S., the company's mission and clinical development programs have a global reach, aiming to provide treatments for millions of people worldwide. A Marketing Authorization Application (MAA) for tanruprubart (ANX005) in Europe for Guillain-Barré syndrome has been filed.

Annexon's brand reputation in the past year appears to be largely positive, particularly within the analyst community. The company has received a consensus rating of "Moderate Buy" from analysts, with a strong bullish sentiment. Analysts have highlighted the company's significant clinical efficacy with ANX005 and the promising regulatory prospects for ANX007. The successful early completion of Phase 3 enrollment for ANX007 and its entry into the EMA's PRIME PDC pilot program have enhanced the credibility of the company's vision preservation label. Strong institutional accumulation and positive analyst coverage following earnings reports and clinical updates have positively affected its reputation. The company's focus on C1q inhibition is seen as a competitive advantage.

Annexon, Inc. has substantial institutional ownership, with 172 institutional owners holding a total of 137,338,504 shares as of April 7, 2026. Major institutional shareholders include Fmr Llc, Redmile Group, LLC, Bvf Inc/il, BlackRock, Inc., Vanguard Group Inc, Adage Capital Partners Gp, L.l.c., Bain Capital Life Sciences Investors, LLC, Bellevue Group AG, State Street Corp, and Ameriprise Financial Inc. Bain Capital Life Sciences Investors LLC owns 9.28% of the company. Overall, institutional shareholders own 114.44% of Annexon stock, while insiders own 23.46%. Key individual and insider owners as of April 11, 2026, include Muneer A Satter, Capital Life Sciences Investors, Llc Bain, and Douglas Love. Insiders have sold more shares than they bought in the past three months, but their overall ownership remains at 11.87% of the stock.